IL23A Gene

IL23A (Interleukin 23 Subunit Alpha)

Overview

IL23A (Interleukin 23 Subunit Alpha) encodes the p19 subunit of interleukin-23 (IL-23), a critical cytokine in the IL-23/Th17 axis that plays a central role in neuroinflammation and immune regulation in neurodegenerative diseases. IL-23 is a heterodimeric cytokine composed of the p19 subunit (encoded by IL23A) and the p40 subunit (encoded by IL12B), forming the functional IL-23 cytokine that drives Th17 cell differentiation and maintenance[@il23_structure].

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | IL23A |
| Full Name | Interleukin 23 Subunit Alpha |
| Chromosomal Location | 12q13.2 |
| NCBI Gene ID | 51561 |
| OMIM ID | 605502 |
| Ensembl ID | ENSG00000110944 |
| UniProt ID | Q9NPF7 |
| Encoded Protein | IL-23 subunit p19 |
| Protein Family | Interleukin-6 family cytokine |
| Molecular Weight | ~19 kDa |

</div>

Gene Structure and Expression

Genomic Organization

The IL23A gene spans approximately 5.5 kb on chromosome 12q13.2 and consists of 6 exons. The gene encodes a 189-amino acid protein that forms the p19 subunit of IL-23. Unlike the IL-12 p40 subunit (IL12B), which is shared with IL-12, the p19 subunit is IL-23-specific and is not expressed constitutively in most tissues.

Expression Patterns

IL23A is expressed in various cell types:

IL23A (Interleukin 23 Subunit Alpha)

Overview

IL23A (Interleukin 23 Subunit Alpha) encodes the p19 subunit of interleukin-23 (IL-23), a critical cytokine in the IL-23/Th17 axis that plays a central role in neuroinflammation and immune regulation in neurodegenerative diseases. IL-23 is a heterodimeric cytokine composed of the p19 subunit (encoded by IL23A) and the p40 subunit (encoded by IL12B), forming the functional IL-23 cytokine that drives Th17 cell differentiation and maintenance[@il23_structure].

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | IL23A |
| Full Name | Interleukin 23 Subunit Alpha |
| Chromosomal Location | 12q13.2 |
| NCBI Gene ID | 51561 |
| OMIM ID | 605502 |
| Ensembl ID | ENSG00000110944 |
| UniProt ID | Q9NPF7 |
| Encoded Protein | IL-23 subunit p19 |
| Protein Family | Interleukin-6 family cytokine |
| Molecular Weight | ~19 kDa |

</div>

Gene Structure and Expression

Genomic Organization

The IL23A gene spans approximately 5.5 kb on chromosome 12q13.2 and consists of 6 exons. The gene encodes a 189-amino acid protein that forms the p19 subunit of IL-23. Unlike the IL-12 p40 subunit (IL12B), which is shared with IL-12, the p19 subunit is IL-23-specific and is not expressed constitutively in most tissues.

Expression Patterns

IL23A is expressed in various cell types:

• Antigen-presenting cells: Dendritic cells, macrophages, and monocytes express IL23A upon activation by pathogen-associated molecular patterns (PAMPs) and danger signals
• B cells: Activated B cells can produce IL-23p19
• Microglia: The resident immune cells of the central nervous system express IL-23 and its receptors
• Neurons: Primary neurons express IL-23 and IL-23R, suggesting autocrine or paracrine signaling in the brain[@il23_neurons]
• Astrocytes: Astrocytic expression of IL-23 has been reported in neuroinflammatory conditions

Transcriptional Regulation

IL23A expression is regulated by various transcription factors including:

• NF-κB (canonical pathway)
• AP-1
• STAT4 (in T cells)
• IRF4 (in dendritic cells)

IL-23/Th17 Pathway in Neuroinflammation

The IL-23/IL-17 Axis

IL-23 is essential for the differentiation, expansion, and maintenance of Th17 cells, which produce IL-17A, IL-17F, IL-21, and IL-22[@th17_differentiation]. This axis has emerged as a critical pathway in neuroinflammation:

IL-17A in Neurodegeneration

IL-17A (encoded by IL17A) is the primary effector cytokine of the Th17 pathway and has been implicated in multiple neurodegenerative conditions:

Alzheimer's Disease:

• IL-17A disrupts neuronal plasticity and memory formation by decreasing brain-derived neurotrophic factor (BDNF) expression[@il17_synapse]
• IL-17A promotes astrocyte-derived neurotrophic factor expression through TRIF-dependent signaling[@il17_gliosis]
• The gut microbiome regulates IL-17 production through propionate-mediated mechanisms affecting Aβ amyloidosis[@gut_microbiome_il17]
• IL-12/IL-23 signaling drives AD pathology through disrupting neuronal and oligodendrocyte homeostasis[@il12_ad_pathology]

• Th17-related cytokines are elevated in the cerebrospinal fluid of PD patients
• IL-17A contributes to dopaminergic neuron loss through microglial activation

• The IL-23/Th17 pathway is central to MS pathogenesis[@il23_ms]
• IL-23R polymorphisms are associated with MS susceptibility

• Th17 cell-related cytokines are elevated in ALS cerebrospinal fluid[@th17_als]
• IL-17A may contribute to motor neuron degeneration

Disease Associations

Alzheimer's Disease

The IL-23/Th17 pathway has been increasingly implicated in Alzheimer's disease pathogenesis:

• Microglial activation and pro-inflammatory cytokine production
• Astrocyte reactivity and gliosis
• Blood-brain barrier disruption
• Synaptic dysfunction and loss

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis and Related Disorders

The IL-23/Th17 pathway is well-established in MS pathogenesis:

• IL-23 drives encephalitogenic Th17 cell differentiation[@gmcsf_th17]
• IL-23R polymorphisms associated with MS susceptibility
• IL-17A contributes to demyelination and axonal injury

Autism Spectrum Disorders

Altered IL-23/IL-17 axis has been reported in serum of patients with autism spectrum disorders[@il23_autism], suggesting potential neurodevelopmental implications.

Molecular Mechanisms

IL-23 Receptor Signaling

The IL-23 receptor complex consists of:

• IL-23R: The specific IL-23 receptor subunit
• IL-12Rβ1: Shared with IL-12 receptor

• JAK-STAT pathway: JAK2/TYK2 activation leading to STAT3 phosphorylation
• MAPK pathway: ERK, JNK, and p38 activation
• NF-κB pathway: Canonical NF-κB activation

Th17 Cell Effector Functions

Th17 cells produce multiple cytokines:

• IL-17A: Pro-inflammatory cytokine acting on various cell types
• IL-17F: Functional homolog of IL-17A
• IL-21: Autocrine cytokine enhancing Th17 differentiation
• IL-22: Epithelial cell activation and protection
• GM-CSF: Granulocyte-macrophage colony-stimulating factor

Signaling Cascade

Therapeutic Implications

Targeting the IL-23/Th17 Pathway

Several therapeutic strategies are being explored:

• Risankizumab (anti-IL-23 p19)
• Guselkumab (anti-IL-23 p19)
• Tildrakizumab (anti-IL-23 p19)

• Secukinumab (anti-IL-17A)
• Ixekizumab (anti-IL-17A)
• Brodalumab (IL-17R blocker)

Clinical Considerations

• Most IL-23/IL-17 targeted therapies are approved for autoimmune diseases (psoriasis, inflammatory bowel disease, rheumatoid arthritis)
• Neurodegenerative applications remain experimental
• Blood-brain barrier penetration is a key consideration
• Timing of intervention may be critical (early vs. late disease)

Challenges in Neurodegeneration

Research Directions

Emerging Areas

Key Unanswered Questions

• What is the precise role of neuronal IL-23/IL-23R signaling?
• How does peripheral IL-23/Th17 immunity communicate with the CNS?
• Can IL-23 inhibition provide neuroprotection in established disease?
• What are the long-term effects of IL-23/Th17 pathway modulation?
• What determines the balance between protective vs. pathogenic Th17 responses?
• How do genetic variants in IL23A/IL23R influence disease risk?

Expression Patterns

Brain Regional Distribution

IL23A shows specific expression patterns across brain regions:

| Region | Expression Level | Notes |
|--------|-----------------|-------|
| Hippocampus | Moderate | Neuronal expression |
| Cortex | Moderate | Neuronal and glial |
| Substantia Nigra | Moderate | Dopaminergic region |
| Cerebellum | Low-Moderate | Limited expression |
| Spinal Cord | Low | Minimal expression |

Cellular Expression

• Neurons: Express IL-23R, respond to IL-23
• Astrocytes: Produce IL-23 under inflammatory conditions
• Microglia: Major producers of IL-23 in CNS
• T cells: Th17 cells are primary IL-23 responsive cells
• Endothelial cells: Express IL-23R, may respond to circulation IL-23

Peripheral Expression

IL23A is expressed in various peripheral tissues:

• Spleen: High in activated dendritic cells
• Lymph nodes: Th17 cell niches
• Gut-associated lymphoid tissue: High IL-23 production
• Skin: Dendritic cell expression
• Lung: Alveolar macrophages

Interaction Network

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|------------------------|
| IL12B (p40) | Protein binding | Forms functional IL-23 |
| IL23R | Receptor | Signal transduction |
| JAK2 | Kinase | Signaling cascade |
| TYK2 | Kinase | Signaling cascade |
| STAT3 | Transcription factor | Gene activation |
| NF-κB | Transcription factor | Inflammatory response |

Pathway Cross-talk

IL-23 signaling intersects with multiple pathways:

Clinical Implications

Biomarker Potential

The IL-23/Th17 pathway shows biomarker potential:

Diagnostic Biomarkers:

• IL-23 levels in CSF correlate with neuroinflammatory conditions
• Th17 cell frequency in peripheral blood as indicator
• IL-17A levels in CSF/serum

• IL-23 pathway activation predicts disease progression
• Changes in Th17 cell numbers correlate with clinical changes

• Target engagement markers for IL-23 blockade
• Predictors of treatment response

Clinical Trials

Current Status:

• No IL-23 targeted trials in neurodegeneration
• Autoimmune trials inform dosing and safety
• Repurposing potential from dermatology/ GI indications

• Patient selection based on biomarker status
• Timing of intervention
• Combination with standard of care
• Long-term follow-up for safety

Therapeutic Development

Agonists vs. Antagonists:

• Antagonists (blocking IL-23) more relevant for neurodegeneration
• Need CNS-penetrant small molecules or novel delivery

• Biologics (antibodies) have limited BBB penetration
• Local delivery approaches being explored
• Nanoparticle-based delivery systems in development

Animal Models

Mouse Models

• IL23A knockout: Viable, Th17 development impaired
• IL23R knockout: Th17 responses absent
• Transgenic overexpression: Enhanced neuroinflammation

Disease Models

AD Models:

• IL-23 levels elevated in APP/PS1 mice
• Anti-IL-23 treatment reduces pathology
• Th17 cells contribute to amyloid-induced inflammation

• Th17 cells increase in MPTP models
• IL-17A contributes to dopaminergic loss
• Targeting IL-17 provides neuroprotection

• IL-23 essential for disease induction
• Blocking IL-23 prevents disease
• Therapeutic translation from mouse to human

Summary

IL23A encodes the p19 subunit of interleukin-23, a cytokine critical for Th17 cell differentiation and function. The IL-23/Th17 pathway has emerged as a key mediator of neuroinflammation in Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. Genetic associations, animal model data, and human studies support a role for this pathway in neurodegeneration. Targeting IL-23 and Th17-related cytokines represents a promising therapeutic strategy for neurodegenerative diseases, though CNS delivery and timing of intervention remain key challenges.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [Th17 Cells](/cell-types/th17-cells)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)
• [IL-12/IL-23 pathway](/mechanisms/il-12-il-23-pathway)
• [Cytokines in neurodegeneration](/mechanisms/cytokines-neurodegeneration)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving IL23A Gene discovered through SciDEX knowledge graph analysis: